{"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"121"}],"units":"Participants"}],"groups":[{"description":"Patients receive dexamethasone IV and low-dose carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with progression cross-over to Arm II.\n\nCarfilzomib: Given IV\n\nDexamethasone: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"BG000","title":"Arm I (Dexamethasone, Low-dose Carfilzomib)"},{"description":"Patients receive dexamethasone IV and high-dose carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose over 2-10 minutes.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\nCarfilzomib: Given IV\n\nDexamethasone: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"BG001","title":"Arm II (Dexamethasone, High-dose Carfilzomib)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"63"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"121"}],"units":"Participants"}],"title":"Age >= 65"},{"categories":[{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"58"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"121"}],"units":"Participants"}],"title":"Age < 65"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"55"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"66"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"121"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"19"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"51"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"92"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"121"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"121"}],"units":"Participants"}]}],"description":"POINT DESCRIPTION 0: Fully active, able to carry on all pre-disease performance without restriction.\n\n1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work.\n2. Ambulatory and capable of self-care but unable to carry out any work activities; up and about more than 50% of waking hours.\n3. Capable of limited self-care, confined to bed or chair more than 50% of waking hours.\n4. Completely disabled; cannot carry on any self-care; totally confined to bed or chair.","paramType":"COUNT_OF_PARTICIPANTS","title":"Zubrod performance status > 1","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"67"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"121"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Beta-2-microglobulin >=3.5 mg/L","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"12"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"56"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Due to missing/not done labs, number analyzed in row differs from overall.","title":"CRP >= 8 mg/L","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"121"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Creatinine >= 2 mg/dl","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"41"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"121"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Creatinine clearance < 60 ml/min","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"57"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"119"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Due to missing/not done labs, number analyzed in row differs from overall.","title":"LDH >= 190 U/L","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"30"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"121"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Albumin < 3.5 g/dl","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"42"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"121"}],"units":"Participants"}]}],"description":"Stage Criteria:\n\nI: Serum β2-microglobulin \\< 3.5 mg/L Serum albumin ≥ 3.5 g/dL II: Not Stage I or III III: Serum β2-microglobulin \\> 5.5 mg/L\n\nNote: Expected survival outcomes worsen with increasing stage.","paramType":"COUNT_OF_PARTICIPANTS","title":"ISS disease stage: Stage 1","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"49"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"121"}],"units":"Participants"}]}],"description":"Stage Criteria:\n\nI: Serum β2-microglobulin \\< 3.5 mg/L Serum albumin ≥ 3.5 g/dL II: Not Stage I or III III: Serum β2-microglobulin \\> 5.5 mg/L\n\nNote: Expected survival outcomes worsen with increasing stage.","paramType":"COUNT_OF_PARTICIPANTS","title":"ISS disease stage: Stage 2","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"30"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"121"}],"units":"Participants"}]}],"description":"Stage Criteria:\n\nI: Serum β2-microglobulin \\< 3.5 mg/L Serum albumin ≥ 3.5 g/dL II: Not Stage I or III III: Serum β2-microglobulin \\> 5.5 mg/L\n\nNote: Expected survival outcomes worsen with increasing stage.","paramType":"COUNT_OF_PARTICIPANTS","title":"ISS disease stage: Stage 3","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"21"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"121"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Hemoglobin <10 g/dL","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"121"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Platelet count < 150 x 10^9/L","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"29"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"121"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"4-6 Prior lines of therapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"60"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"121"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Refractory to Bortezomib","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"19"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"120"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Due to missing/not done labs, number analyzed in row differs from overall.","title":"Serum M spike >3 g/dL","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"25"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"119"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Due to missing/not done labs, number analyzed in row differs from overall.","title":"Bone marrow plasma cells > 60%","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"43"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"111"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Due to missing/not done labs, number analyzed in row differs from overall.","title":"sLFC Ratio >=100","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"60"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"61"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"115"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Due to missing/not done labs, number analyzed in row differs from overall.","title":"Myeloma isotype: IgG","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"17"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"61"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"115"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Due to missing/not done labs, number analyzed in row differs from overall.","title":"Myeloma isotype: IgA","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"17"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"61"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"115"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Due to missing/not done labs, number analyzed in row differs from overall.","title":"Myeloma isotype: light chain only","unitOfMeasure":"Participants"}],"populationDescription":"Includes patients who were eligible and analyzable for study endpoints (indicated as \"Completed\" in participant flow)."}